VP1-2023: Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study
Titel:
VP1-2023: Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study
Auteur:
Rha, S.Y. Wyrwicz, L.S. Weber, P.E.Y. Bai, Y. Ryu, M.H. Lee, J. Rivera, F. Alves, G.V. Garrido, M. Shiu, K-K. Fernández, M. González Li, J. Lowery, M. Cil, T. Cruz, F.J.S.M. Qin, S. Yin, L. Bordia, S. Bhagia, P. Oh, D-Y.